Zhan HQ, Zhou JL, Zhang J, Wu D, Gu CY. Conbercept combined with laser photocoagulation in the treatment of diabetic macular edema and its influence on intraocular cytokines. World J Diabetes 2023; 14(8): 1271-1279 [PMID: 37664482 DOI: 10.4239/wjd.v14.i8.1271]
Corresponding Author of This Article
Chun-Yan Gu, MM, Attending Doctor, Department of Ophthalmology, The Third People’s Hospital of Changzhou, No. 300 Lanling North Road, Tianning District, Changzhou 213001, Jiangsu Province, China. gchy0102@126.com
Research Domain of This Article
Ophthalmology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Aug 15, 2023; 14(8): 1271-1279 Published online Aug 15, 2023. doi: 10.4239/wjd.v14.i8.1271
Conbercept combined with laser photocoagulation in the treatment of diabetic macular edema and its influence on intraocular cytokines
Hui-Qin Zhan, Ji-Lin Zhou, Jun Zhang, De Wu, Chun-Yan Gu
Hui-Qin Zhan, Ji-Lin Zhou, Jun Zhang, De Wu, Chun-Yan Gu, Department of Ophthalmology, The Third People’s Hospital of Changzhou, Changzhou 213001, Jiangsu Province, China
Author contributions: Zhan HQ designed and performed the research and wrote the paper; Gu CY designed the research and supervised the report; Zhou JL designed the research and contributed to the analysis; Zhang J and Wu D provided clinical advice.
Supported bythe Youth Project of Changzhou Health Commission, No. QN202129.
Institutional review board statement: This study was reviewed and approved by the Third People’s Hospital of Changzhou.
Informed consent statement: This study has obtained informed consent from all patients.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: Does not support sharing data with third parties.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chun-Yan Gu, MM, Attending Doctor, Department of Ophthalmology, The Third People’s Hospital of Changzhou, No. 300 Lanling North Road, Tianning District, Changzhou 213001, Jiangsu Province, China. gchy0102@126.com
Received: May 31, 2023 Peer-review started: May 31, 2023 First decision: June 14, 2023 Revised: June 19, 2023 Accepted: July 14, 2023 Article in press: July 14, 2023 Published online: August 15, 2023
ARTICLE HIGHLIGHTS
Research background
China has a high prevalence of diabetes and a large base of diabetes. Diabetic retinopathy (DR) seriously affects the patients’ quality of life.
Research motivation
DR is an important condition affecting people’s lives, health, and economic development. Therefore, effective and efficient treatment programs are required.
Research objectives
To provide better treatment for DR with macular edema.
Research methods
We selected 130 patients with diabetic macular edema who were hospitalized between January 2018 and May 2020 and assigned them to the following two groups according to treatment: the observation and control groups. The control group was treated with laser photocoagulation, and the observation group received laser photocoagulation with an intravitreal injection of conbercept (65 patients in each group). Clinical efficacy was evaluated, and seven indicators were measured.
Research results
The total efficacy rate in the observation group (93.85%) was higher than that in the control group (78.46%). In both groups, the BCVA correction effect was better after treatment, and that in the observation group was superior to that in the control group. Retinal thickness and CMT improved after treatment, and the observation group was superior to the control group. The levels of VEGF, IL-6, sICAM-1, and BFGF in both groups improved after treatment, and the observation group was superior to the control group.
Research conclusions
In patients with macular edema, the combination of laser photocoagulation and intravitreal injections of Conbercept for DME is a more effective and safer way to improve vision, reduce retinal thickness, and lower intraocular cytokine VEGF levels.
Research perspectives
It is more effective in treating DR with macular edema and is worthy of widespread promotion.
